Source: Annual Congress 2010 - Management of airway disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Martin, R. Stanford, P. Dale, S. Fehnl (Ann Arbor, RTP, United States Of America; London, United Kingdom). What represents a meaningful improvement in symptom-free days (SFD) and rescue-free days (RFD)? The patient‘s perspective. Eur Respir J 2010; 36: Suppl. 54, 4555

Member's Comments

No comment yet.

Related content which might interest you: Asthma control (AC) and quality of life (QoL) 3 months after pulmonary rehabilitation (PR) Source: Annual Congress 2010 - Pulmonary rehabilitation: understanding and developing the intervention Year: 2010 The incremental shuttle walk test (ISW) in patients with bronchiectasis: Response to pulmonary rehabilitation (PR) and minimum clinically important difference (MCID) Source: International Congress 2019 – Hot topics in pulmonary rehabilitation Year: 2019 An increase in steps per day 6 weeks after pulmonary rehabilitation of COPD patients correlates with an improvement in quality of life Source: Virtual Congress 2020 – Optimising the benefits of pulmonary rehabilitation Year: 2020 Fluticasone/salmeterol combination (FSC) is safe and provides effective long-term (52 week) control in the management of patients with persistent asthma (PA) Source: Eur Respir J 2001; 18: Suppl. 33, 176s Year: 2001 Minimal clinically important differences for Dyspnea-12 and MDP scores are similar at 2 weeks and 6 months: follow-up of a longitudinal clinical study Source: Eur Respir J, 57 (3) 2002823; 10.1183/13993003.02823-2020 Year: 2021 Dose selection and pharmacokinetics of montelukast (sprinkles) in >=6 month to <2 year old asthmatic patients Source: Eur Respir J 2002; 20: Suppl. 38, 525s Year: 2002 Decline in 4-metre gait speed (4MGS) over 6 months is associated with mortality in IPF. Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia Year: 2019 LATE-BREAKING ABSTRACT: The minimal clinically important difference (MCID) for the six minute walk (6MW) test in COPD in relation to death Source: Annual Congress 2012 - The latest insights in chronic care Year: 2012 Who win? Spirometry versus symptoms for predicting the longitudinal outcomes in COPD patients – 10 years observation Source: Annual Congress 2011 - Clinical parameters in airway diseases Year: 2011 Trajectory of patient-reported outcomes (PROMs) up to 6 months after hospitalization for SARS-CoV-2 Source: Virtual Congress 2021 – Long COVID - 19 Year: 2021 Influence of an incentive spacer on adherence to prescribed treatment in 2-6 year old children over a 3 month period Source: Annual Congress 2007 - Childhood asthma: treatment and follow-up Year: 2007 Sustainability of use of an electronic health journal (patientMpower) for pulmonary fibrosis in a US patient support group (PF Warriors) over 180 days. Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018 Degree of exercise limitation in COPD: impact on 6 minute walk (6MW) in response to long-acting β-agonist (LABA) treatment Source: Eur Respir J 2007; 30: Suppl. 51, 76s Year: 2007 Indacaterol/glycopyrronium (IND/GLY) reduces days with COPD exacerbation vs salmeterol/fluticasone (SFC) independent of PRO tool: results of the FLAME study Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Changes in subjective assessments during 2 and 4 weeks of a nasal CPAP (nCPAP) trial? Source: Eur Respir J 2002; 20: Suppl. 38, 101s Year: 2002 LATE-BREAKING ABSTRACT: RESPIRE 1: Ciprofloxacin DPI 32.5mg b.d. administered 14 day on/off or 28 day on/off vs placebo for 48 weeks in subjects with non-cystic fibrosis bronchiectasis (NCFB) Source: International Congress 2016 – Clinical update on bronchiectasis Year: 2016 Longterm [7 year] follow-up of patients fitted with a non-adjustable intra-oral device (IOD) for snoring/obstructive sleep apnoea (OSAS) Source: Eur Respir J 2004; 24: Suppl. 48, 477s Year: 2004 Montelukast is safe and well tolerated in >=6 month to <2 year old patients Source: Eur Respir J 2002; 20: Suppl. 38, 525s Year: 2002 How does regular exercise affect dyspnoe (TDI) and quality of life (CAT) of COPD-patients 1 year after an inpatient pulmonary rehabilitation (PR)? Source: International Congress 2015 – Latest insights into pulmonary rehabilitation Year: 2015 Efficacy, safety and tolerability of 3 day azithromycin (A) versus 10-day conventional treatment (CT) in the treatment of children with acute asthma exacerbation (AE) Source: Eur Respir J 2005; 26: Suppl. 49, 135s Year: 2005